Breast Cancer Research - Volume 7, issue 5

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras neque tellus, ornare vel pulvinar luctus, vestibulum malesuada ante. Nullam pellentesque, ipsum vel fermentum tincidunt, velit neque molestie lacus, at iaculis purus mauris in nisl. Nullam vehicula imperdiet auctor. Mauris tempus, leo eget euismod condimentum, erat justo vehicula augue, vitae ornare elit felis nec libero. Etiam et quam sit amet metus dignissim dictum sed vitae purus. Phasellus gravida hendrerit risus vitae euismod. In elementum massa facilisis nulla pulvinar at pharetra leo pellentesque.

Electronic ISSN
1465-542X
Print ISSN
1465-5411

Abstract

Early stopping of clinical trials in favour of a new treatment creates ethical and scientific difficulties, which are different from those associated with early stopping due to toxicity or futility. Two major breast cancer trials have recently taken such a decision, and the problem is relevant fo

Journal: Breast Cancer Research, vol. 7, no. 5, 2005

Abstract

Introduction

Endocrine therapy is the most important treatment option for women with hormone-receptor-positive breast cancer. The potential mechanisms for endocrine resistance involve estrogen receptor (ER)-coregulatory proteins and crosstalk between ER and other growth factor signaling networks.

Journal: Breast Cancer Research, vol. 7, no. 5, 2005